{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:22:27Z","timestamp":1790572947067,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Clinical Research from the National Hospital Organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The transient receptor potential cation channel subfamily V member 2 (TRPV2) is a stretch-sensitive calcium channel. TRPV2 overexpression in the sarcolemma of skeletal and cardiac myocytes causes calcium influx into the cytoplasm, which triggers myocyte degeneration. In animal models of cardiomyopathy and muscular dystrophy (MD), TRPV2 inhibition was effective against heart failure and motor function. Our previous pilot study showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide (BNP) levels in two MD patients with advanced heart failure. Thus, this single-arm, open-label, multicenter study aimed to evaluate the safety and efficacy of tranilast for heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study enrolled MD patients with advanced heart failure whose serum BNP levels were\u2009&gt;\u2009100\u00a0pg\/mL despite receiving standard cardioprotective therapy. Tranilast was administered orally at 100\u00a0mg, thrice daily. The primary endpoint was the change in log (BNP) (\u0394log [BNP]) at 6\u00a0months from baseline. The null hypothesis was determined based on a previous multicenter study of carvedilol results in a mean population \u0394log (BNP) of 0.18. TRPV2 expression on peripheral blood mononuclear cell surface, cardiac events, total mortality, left ventricular fractional shortening, human atrial natriuretic peptide, cardiac troponin T, and creatine kinase, and pinch strength were also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Because of the poor general condition of many patients, only 18 of 34 patients were included and 13 patients could be treated according to the protocol throughout the 6-month period. However, there were no serious adverse events related to tranilast except diarrhea, a known adverse effect, and the drug was administered safely. TRPV2 expression on the mononuclear cell surface was elevated at baseline and reduced after treatment. Cardiac biomarkers such as BNP, human atrial natriuretic peptide, and fractional shortening remained stable, suggesting a protective effect against the progression of heart failure. In the per protocol set group, \u0394log [BNP] was \u2212\u20090.2 and significantly lower than that in the null hypothesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tranilast is safe and effective in inhibiting TRPV2 expression, even in MD patients with advanced heart failure. Further trials are needed to evaluate the efficacy of tranilast in preventing myocardial damage, heart failure, motor impairment, and respiratory failure.<\/jats:p>\n                <jats:p><jats:italic>Clinical trial registration<\/jats:italic> The study was registered in the UMIN Clinical Trials Registry (UMIN-CTR: UMIN000031965, URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.ac.jp\/ctr\/\">http:\/\/www.umin.ac.jp\/ctr\/<\/jats:ext-link>) [March 30, 2018] and the Japan Registry of Clinical Trials (jRCT, registration number: jRCTs031180038, URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/\">https:\/\/jrct.niph.go.jp\/<\/jats:ext-link>) [November 12, 2021]. Patient registration was started in December 19, 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02352-3","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:05:41Z","timestamp":1652699141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-3626","authenticated-orcid":false,"given":"Tsuyoshi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Motoyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Fukudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2352_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.5692\/clinicalneurol.51.743","volume":"51","author":"T Matsumura","year":"2011","unstructured":"Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2011;51:743\u201350. https:\/\/doi.org\/10.5692\/clinicalneurol.51.743.","journal-title":"Rinsho Shinkeigaku"},{"key":"2352_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/01.RES.0000097263.10220.0C","volume":"93","author":"K Muraki","year":"2003","unstructured":"Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, et al. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res. 2003;93:829\u201338. https:\/\/doi.org\/10.1161\/01.RES.0000097263.10220.0C.","journal-title":"Circ Res"},{"key":"2352_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1083\/jcb.200301101","volume":"161","author":"Y Iwata","year":"2003","unstructured":"Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor\u2014regulated channel. J Cell Biol. 2003;161:957\u201367. https:\/\/doi.org\/10.1083\/jcb.200301101.","journal-title":"J Cell Biol"},{"key":"2352_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cvr\/cvt163","volume":"99","author":"Y Iwata","year":"2013","unstructured":"Iwata Y, Ohtake H, Suzuki O, Matsuda J, Komamura K, Wakabayashi S. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res. 2013;99:760\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvt163.","journal-title":"Cardiovasc Res"},{"key":"2352_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bcp.2005.05.034","volume":"70","author":"Y Iwata","year":"2005","unstructured":"Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M, et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol. 2005;70:740\u201351. https:\/\/doi.org\/10.1016\/j.bcp.2005.05.034.","journal-title":"Biochem Pharmacol"},{"key":"2352_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/hmg\/ddn408","volume":"18","author":"Y Iwata","year":"2009","unstructured":"Iwata Y, Katanosaka Y, Arai Y, Shigekawa M, Wakabayashi S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet. 2009;18:824\u201334. https:\/\/doi.org\/10.1093\/hmg\/ddn408.","journal-title":"Hum Mol Genet"},{"key":"2352_CR7","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1016\/j.febslet.2009.10.033","volume":"583","author":"N Zanou","year":"2009","unstructured":"Zanou N, Iwata Y, Schakman O, Lebacq J, Wakabayashi S, Gailly P. Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions. FEBS Lett. 2009;583:3600\u20134. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.033.","journal-title":"FEBS Lett"},{"key":"2352_CR8","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.18632\/oncotarget.24449","volume":"9","author":"Y Iwata","year":"2018","unstructured":"Iwata Y, Katayama Y, Okuno Y, Wakabayashi S. Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model. Oncotarget. 2018;9:14042\u201357. https:\/\/doi.org\/10.18632\/oncotarget.24449.","journal-title":"Oncotarget"},{"key":"2352_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41374-019-0363-1","volume":"100","author":"Y Iwata","year":"2020","unstructured":"Iwata Y, Wakabayashi S, Ito S, Kitakaze M. Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models. Lab Investig. 2020;100:324\u201337. https:\/\/doi.org\/10.1038\/s41374-019-0363-1.","journal-title":"Lab Investig"},{"key":"2352_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2169\/internalmedicine.8651-16","volume":"57","author":"T Matsumura","year":"2018","unstructured":"Matsumura T, Matsui M, Iwata Y, Asakura M, Saito T, Fujimura H, et al. A pilot study of tranilast for cardiomyopathy of muscular dystrophy. Intern Med. 2018;57:311\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.8651-16.","journal-title":"Intern Med"},{"key":"2352_CR11","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/ijms20163844","volume":"20","author":"Y Iwata","year":"2019","unstructured":"Iwata Y, Matsumura T. Blockade of TRPV2 is a novel therapy for cardiomyopathy in muscular dystrophy. Int J Mol Sci. 2019;20:3844. https:\/\/doi.org\/10.3390\/ijms20163844.","journal-title":"Int J Mol Sci"},{"key":"2352_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2739\/kurumemedj.MS662006","volume":"66","author":"T Matsumura","year":"2021","unstructured":"Matsumura T, Hashimoto H, Sekimizu M, Saito AM, Iwata Y, Asakura M, et al. Study protocol for a multicenter, open-label, single-arm study of tranilast for cardiomyopathy of muscular dystrophy. Kurume Med J. 2021;66:121\u20136. https:\/\/doi.org\/10.2739\/kurumemedj.MS662006.","journal-title":"Kurume Med J"},{"key":"2352_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.nmd.2004.08.002","volume":"14","author":"J Demachi","year":"2004","unstructured":"Demachi J, Kagaya Y, Watanabe J, Sakuma M, Ikeda J, Kakuta Y, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord. 2004;14:732\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2004.08.002.","journal-title":"Neuromuscul Disord"},{"key":"2352_CR14","first-page":"593","volume":"30","author":"N Takekoshi","year":"1996","unstructured":"Takekoshi N, Kanemitsu S, Kitayama M, Masuyama K, Kanaya H, Namura M, et al. Percutaneous transluminal coronary angioplasty (PTCA) -a phase III multicenter open trial. Kiso Rinsho. 1996;30:593\u2013609.","journal-title":"Kiso Rinsho"},{"key":"2352_CR15","first-page":"65","volume":"12","author":"K Kato","year":"1996","unstructured":"Kato K, Tamai H, Hayakawa H, Yamaguchi T, Kanmatsuse K, Haze K, et al. Clinical evaluation of tranilast on restenosis after percutaneous transluminal coronary angiopathy (PTCA)\u2014a double-blind placebo-controlled comparative study. Rinsho Iyaku. 1996;12:65\u201385.","journal-title":"Rinsho Iyaku"},{"key":"2352_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.braindev.2007.01.009","volume":"29","author":"T Matsumura","year":"2007","unstructured":"Matsumura T, Saito T, Fujimura H, Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev. 2007;29:496\u2013501. https:\/\/doi.org\/10.1016\/j.braindev.2007.01.009.","journal-title":"Brain Dev"},{"key":"2352_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.nmd.2021.04.008","volume":"31","author":"T Matsumura","year":"2021","unstructured":"Matsumura T, Takada H, Kobayashi M, Nakajima T, Ogata K, Nakamura A, et al. A Web-based questionnaire survey on the influence of coronavirus disease-19 on the care of patients with muscular dystrophy. Neuromuscul Disord. 2021;31:839\u201346. https:\/\/doi.org\/10.1016\/j.nmd.2021.04.008.","journal-title":"Neuromuscul Disord"},{"key":"2352_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2169\/internalmedicine.49.3259","volume":"49","author":"T Matsumura","year":"2010","unstructured":"Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med. 2010;49:1357\u201363. https:\/\/doi.org\/10.2169\/internalmedicine.49.3259.","journal-title":"Intern Med"},{"key":"2352_CR19","first-page":"123","volume":"16","author":"N Madokoro","year":"2013","unstructured":"Madokoro N, Ito Y. The occupational therapy effect for Duchenne muscular dystrophy patients by the randomized clinical trial. J Jpn Health Sci. 2013;16:123\u201332.","journal-title":"J Jpn Health Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02352-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02352-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02352-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:12:25Z","timestamp":1652699545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02352-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2352"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02352-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the National Hospital Organization Review Board for Clinical Trials and the panel of Advanced Medical Technology of Health, Labour and Welfare Ministry. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable as the manuscript does not contain any identifiable individual person\u2019s data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}